enGene Therapeutics Inc. Adjustments to Additional Paid in Capital, Warrant Issued
enGene Therapeutics Inc. (ENGN) reported Adjustments to Additional Paid in Capital, Warrant Issued of $411.00 thousand for the 3-month period ending 2026-01-31, per its 10-Q filed 2026-09-08.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-09-08
- enGene Therapeutics Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-01-31 was $411.00K.
- enGene Therapeutics Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-01-31 was $319.00K.
- enGene Therapeutics Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $319.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2026-01-31 | $411.00K 10-Q · filed 2026-09-08 | |
| 2024-10-31 | $319.00K 10-K · filed 2025-12-22 | |
| 2024-01-31 | $319.00K 10-Q · filed 2025-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |